---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-086486"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:21:41.700770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences Q3 2023 net income $0.1M vs loss of $0.4M year ago

## Summary
- Q3 net revenues $5.0M, up from $4.9M in Q3 2022; nine-month revenues $22.5M vs $12.5M.
- Q3 income from operations $0.02M, compared to operating loss of $0.7M in Q3 2022.
- Net loss for nine months 2023 was $4.9M ($0.09/share), improved from $10.8M ($0.22/share) in 2022.
- Inventory shortage of Endari caused lower Q3 sales; remedied, expects recovery in Q4.
- Cash and cash equivalents $1.5M at Sep 30, 2023, down from $2.0M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001213900-23-086486
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/ea188263-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-086486
- JSON: https://secwatch.observer/filing/0001213900-23-086486.json
- Plain text: https://secwatch.observer/filing/0001213900-23-086486.txt

## Key facts
- Earnings Releases
  Emmaus Life Sciences, Inc. reported the three months ended September 30, 2023 results: net income net income of $0.1 million, EPS $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha.
  - Period: the three months ended September 30, 2023
  - Net income: net income of $0.1 million
  - EPS: $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha
  - Result: reported results
  source text: For the quarter, the company realized net income of $0.1 million, or $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per share based on approximately 138.4 million weighted average diluted common shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm
- Earnings Releases
  Emmaus Life Sciences, Inc. reported the three and nine months ended September 30, 2023 results: revenue $5.0 million and $22.5 million, respectively.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: $5.0 million and $22.5 million, respectively
  - Result: reported results
  source text: Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for same periods in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm
- Earnings Releases
  Emmaus Life Sciences, Inc. reported the nine months ended September 30, 2023 results: net income net loss of $4.9 million, EPS $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.
  - Period: the nine months ended September 30, 2023
  - Net income: net loss of $4.9 million
  - EPS: $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares
  - Result: reported results
  source text: For the nine months ended September 30, 2023, the company reported a net loss of $4.9 million, or $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.